Sotera Health

Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. It also provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. The firm operates through the following businesses: Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets by using following technologies: gamma irradiation, EO processing and E-beam irradiation. The Nordion business provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was founded in 1978 and is headquartered in Broadview Heights, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sotera Health reports solid Q4 growth, cautious outlook for 2023

Sotera Health delivered growth in Q4 2022, closed a major litigation settlement, and outlined a cautious outlook for 2023. Strategic investments in EO enhancements and pharma growth signal long-term vision, while challenges in revenue and adjusted EPS are acknowledged. Overall, the company remains optimistic about future growth prospects.

Sotera Health reports Q1 revenue decline, eyes growth opportunities

Sotera Health faced revenue and EBITDA declines in Q1 2023 but remains optimistic about future growth prospects.
The company is addressing challenges in inflation, labor, and supply chains while focusing on operational improvements.
Opportunities for revenue growth exist through Nordion volumes, facility enhancements, and regulatory compliance efforts.
Overall, Sotera Health's performance reflects a mix of challenges, strengths, and opportunities for strategic advancement.

Sotera Health releases settlement funds, faces revenue declines in Q2

Sotera Health navigated challenges in Q2 2023 with declines in revenues and adjusted EBITDA but showcased strengths in strategic planning and operational efficiency.
The company's outlook remains positive, with opportunities for growth through capacity expansions and improved volumes in the second half of the year.
Addressing challenges in revenue performance and customer inventory levels will be crucial for sustaining growth and investor confidence.
Proactive measures and transparent communication underscore Sotera Health's commitment to navigating market uncertainties and driving long-term success.

Sotera Health reports revenue growth amidst challenges and opportunities

Sotera Health (SHC) delivered a mixed performance in Q3 2023 with revenue growth, margin improvement, and operational challenges.
The company maintains a strong liquidity position and is actively managing its financial metrics to drive long-term growth.
While facing challenges from external factors, Sotera Health (SHC) has opportunities to enhance efficiency and capitalize on growth prospects.

Sotera Health (SHC) posts robust Q4 results, eyes 2024 growth

Sotera Health (SHC) delivered strong financial performance in Q4 2023 and full year.
Operational achievements and resolved litigation bolstered the company's position.
Challenges include potential impact on revenue growth from Nordion contracts.
Optimistic outlook for 2024 with a focus on customer value and safety.

Sotera Health (SHC) reports robust Q1 performance and growth outlook

Sotera Health (SHC) delivered strong Q1 2024 results, reaffirming growth outlook and showcasing financial resilience.
Management's confidence in defense against lawsuits and compliance with regulations, alongside strategic investments, underpin the company's stability and growth potential.
With a focus on operational efficiency, capacity expansions, and investor engagement, Sotera Health (SHC) is poised for sustainable growth and value creation.

Sotera Health posts robust Q2 results, eyes efficiency and growth

Sotera Health delivered strong financial results in Q2 2024, supported by revenue growth and operational improvements across key segments.
Despite challenges such as FX headwinds and macroeconomic uncertainties, the company's solid liquidity position and debt refinancing strengthen its financial foundation.
Opportunities lie in optimizing cash flow, managing capital expenditures, and leveraging new board expertise for sustained growth and value creation.

Sotera Health reports robust Q3 growth, affirms 2024 outlook

Sotera Health's Q3 2024 performance reflects strong revenue and EBITDA growth across key business segments, underlining operational efficiency and market demand.
While facing challenges in regulatory compliance and market dynamics, the company's diverse strengths in critical sectors and upcoming Investor Day signal resilience and strategic focus.
By addressing challenges, leveraging opportunities, and maintaining growth momentum, Sotera Health aims to sustain its positive performance trajectory and investor appeal in the competitive landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Settlement Explicitly Does Not Constitute Admission of Liability Settlement Explicitly Does Not Constitute Admission of Liability

Sotera Health Announces Settlement of Ethylene Oxide Litigation in Illinois

CLEVELAND, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today is presenting at the 41st Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health's business.

Sotera Health Chairman and CEO Presents at 41st Annual J.P. Morgan Healthcare Conference

CLEVELAND, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 pm Eastern. In his presentation, Mr. Petras will provide an update on Sotera Health's business. Mr. Petras and Jason Peterson, Vice President and Treasurer, will participate in one-on-one meetings with investors during the conference.

Sotera Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

OAK BROOK, Ill., Nov. 21, 2022 (GLOBE NEWSWIRE) -- In response to numerous inquiries, Sterigenics®, a business of Sotera Health (Nasdaq: SHC), and a global leader in comprehensive sterilization services, today issued the following statement regarding the verdict in favor of the Company in the Fornek trial:

Sterigenics Issues Statement on Favorable Verdict in Fornek Trial

It's a great day to be invested in Sotera Health (NASDAQ: SHC ). The company just received a favorable verdict from court.

Why Is Sotera Health (SHC) Stock Up 35% Today?

Sotera Health Company (NASDAQ:SHC ) Q3 2022 Earnings Conference Call November 2, 2022 9:00 AM ET Company Participants Jason Peterson - Vice President and Treasurer Michael Petras - Chairman and Chief Executive Officer Michael Biehl - Interim Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Phil Coover - Goldman Sachs Matt Mishan - KeyBanc Mike Polark - Wolfe Research Operator Good morning. My name is Denise, and I will be your conference call operator today.

Sotera Health Company (SHC) Q3 2022 Earnings Call Transcript

Sotera Health Company (SHC) delivered earnings and revenue surprises of 4.55% and 1.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sotera Health Company (SHC) Q3 Earnings and Revenues Surpass Estimates

CLEVELAND, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the third quarter and first nine months of 2022.

Sotera Health Reports Third-Quarter and Year-to-Date 2022 Results

Global business leader, distinguished general counsel and big law partner to join Sotera Health Global business leader, distinguished general counsel and big law partner to join Sotera Health

Sotera Health Announces Alex Dimitrief as General Counsel

Today, we put Sotera Health Company in the spotlight for the first time. Despite steady revenue growth and low valuations, the stock has been hit hard by recent litigation challenges.

Sotera Health: Litigation Looms Large

AppLovin Corp

Enovix Corporation

NeoGenomics

1Life Healthcare

Prometheus Biosciences

Signify Health

Scotts Miracle-Gro

Verve Therapeutics

WeWork

Mid-cap companies are those that fall between small and large cap companies. Thus, they are more stable than small-cap companies and, at the same time, offer higher growth opportunities than large-cap companies.

These Were The Five Best And Worst Performing Mid-Cap Stocks In Q3 2022

CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third quarter ended September 30, 2022 before market open on Wednesday, November 2, 2022. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results.

Sotera Health Announces Third-Quarter 2022 Earnings Release Date

AMC Entertainment

Altice USA

Cano Health

Cricut

Eve Holding Inc

Getty Images Holdings Inc

IVERIC bio Inc

NCR Corporation

Revance Therapeutics

Mid-cap stocks are a good choice for investors who are okay with relatively more volatility to get some extra returns.

These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022

NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sotera Health Company (""Sotera" or the "Company") (NASDAQ: SHC). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sotera Health Company - SHC

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Sotera Health Company (“Sotera” or the “Company”) (NASDAQ: SHC) on behalf of Sotera stockholders. Our investigation concerns whether Sotera has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On September 19, 2022, news outlets reported that a jury found Sotera

SOTERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sotera Health Company on Behalf of Sotera Stockholders and Encourages Investors to Contact the Firm

Atlanta, Georgia--(Newsfile Corp. - September 22, 2022) - Holzer & Holzer, LLC is investigating whether Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ: SHC) complied with federal securities laws. On September 19, 2022, The Chicago Sun-Times reported that a jury found Sotera Health's Sterigenics business unit liable for a role in causing a woman's breast cancer due to its release of emissions from the Company's plant and awarded the plaintiff $363 million.

SHAREHOLDER ALERT: Investigation of Sotera Health (SHC) Announced by Holzer & Holzer, LLC

A tough legal defeat is making analysts much more bearish on the company.

Why Sotera Health Got Slammed Again on Wednesday

An analyst's new take on the company has investors scrambling for the exits.

Why Sotera Health Stock Tumbled Again on Tuesday

Why Sotera Health Stock Crumbled Today

Sotera Health Company (NASDAQ:SHC ) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Joe Vitale - VP, IR Michael Petras - Chairman and CEO Michael Biehl - Interim CFO Conference Call Participants Lizzie Speyer - Citi Casey Woodring - JPMorgan Michael Polark - Wolfe Research Matthew Mishan - KeyBanc Ben Flox - Jefferies Luke Sergott - Barclays Thomas Kelliher - RBC Capital Markets Operator Good morning. My name is Howard and I will be your conference call operator today.

Sotera Health Company (SHC) CEO Michael Petras on Q2 2022 Results Earnings Call Transcript

Sotera Health Company (SHC) delivered earnings and revenue surprises of 12.50% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sotera Health Company (SHC) Tops Q2 Earnings and Revenue Estimates

Names Michael F. Biehl as Interim Chief Financial Officer Names Michael F. Biehl as Interim Chief Financial Officer

Sotera Health Announces Second-Quarter 2022 Earnings Release Date

Sotera Health Company (SHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Sotera Health Company (SHC) Stock Jumps 6.5%: Will It Continue to Soar?

The company is about to become a component of an important equity index.

Why Sotera Health Stock Crushed the Market Today

CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced the departure of Scott Leffler, Sotera Health's Chief Financial Officer (CFO). After over five years at Sotera Health, Leffler has accepted another CFO role and will be relocating to Florida. To support an orderly transition, Leffler will remain at Sotera Health until August 12, 2022.

News for Sotera Health Stock (SHC)